This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08939/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08939
rdf:type
n3:Drug
n3:description
Letosteine is a mucolytic used in the treatment of chronic bronchopneumopathies and related conditions.
n3:generalReferences
# Liu X, Zheng H, Tang W, Qian Z, Zhu Y, Wang J, Yuan S, Wen X, Cao C, Chen H: Development of a novel LC-MS/MS method for the determination of letosteine in human plasma and its application on pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2554-60. doi: 10.1016/j.jchromb.2011.07.011. Epub 2011 Jul 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21840272
n3:group
experimental
owl:sameAs
n7:DB08939
dcterms:title
Letosteine
adms:identifier
n9:DB08939
n3:IUPAC-Name
n4:271B5E4D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E53-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E52-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E4F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E50-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E51-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E4B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E4C-363D-11E5-9242-09173F13E4C5 n4:271B5E49-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E4A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5E59-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E5A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E54-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E55-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E57-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E56-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E58-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
53943-88-7
n3:Bioavailability
n4:271B5E5F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E61-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E62-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E5E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E5D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E60-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E4E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E5B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E5C-363D-11E5-9242-09173F13E4C5